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Abstract
Objective: To investigate whether osteocytic connexin 43 (Cx43) is required for the bone response to intermittent PTH administra-
tion, and whether the connexin is involved in maintaining the bone matrix. Methods: Human PTH(1-34) was injected to adult male 
mice expressing (Cx43fl/fl) or not osteocytic Cx43 (Cx43fl/fl;DMP1-8kb-Cre) daily (100 μg/kg/d) for 14 days. Results: Cx43fl/fl;DMP1-
8kb-Cre mice have no difference in body weight and BMD from 1 to 4 months of age. Intermittent PTH administration increased BMD 
and BV/TV and induced a similar increase in type I collagen, alkaline phosphatase, runx2, osteocalcin, and bone sialoprotein expres-
sion in mice from both genotypes. On the other hand, osteocytic deletion of Cx43 did not alter mRNA levels of glycosaminoglycans, 
proteoglycans, collagens and osteoblast-related genes. In addition, expression of collagens assessed by immunohistochemistry was not 
affected by deleting osteocytic Cx43. However, PTH administration increased type II collagen only in Cx43fl/fl control mice, whereas 
hormone increased type I collagen expression only in Cx43fl/fl;DMP1-8kb-Cre mice. Furthermore, PTH increased maturity of collagen 
fibers in control, but not in Cx43-deficient mice. Conclusion: Expression of Cx43 in osteocytes is dispensable for bone anabolism 
induced by intermittent PTH administration; but it can modulate, at least in part, the effect of PTH on the bone matrix environment.
Keywords: Bone Matrix, Collagen, Connexin 43, Osteocyte, PTH
Introduction
The combination of mineral, collagen, non-collagenous pro-
teins, lipids and water provide elasticity and stiffness to the bone, 
contributing to bone strength and, consequently, preventing bone 
fractures. Osteoblasts are the bone cells responsible for extracel-
lular bone matrix deposition, which initially is non-mineralized 
(osteoid) and will later become mineralized1,2. Osteocytes have 
now been implicated in maintaining the bone matrix by digest-
ing matrix in some circumstances and acting as endocrine cells, 
regulating phosphate metabolism3,4. The two important elements 
that constitute the organic phase in the bone matrix are the col-
lagen proteins, the basic unit of the matrix fiber network, and 
the proteoglycans5,6. The basic proteoglycan units include a core 
protein attached covalently to one or more glycosaminoglycans 
(GAGs) such as heparin, heparan sulfate, dermatan sulfate, kera-
tan sulfate, and chondroitin sulfate. In addition to these GAGs, 
hyaluronan is also present in the bone matrix, but is different 
from others members of the family in that is not sulfated and 
does not bind to a core protein7.
Several drugs with anti-resorptive action have been used to 
stop bone loss and thus prevent osteoporosis, a condition char-
acterized by low bone mass and high risk of fractures8. Some 
of these drugs include bisphosphonates (alendronate, risedronate, 
pamidronate, zoledronic acid), raloxifene, denosumab, and calci-
tonin. Intermittent PTH administration is the only anabolic treat-
ment currently approved by the Food and Drug Administration 
(FDA) to increase bone mass in patients suffering from severe 
osteoporosis. Daily injections of the hormone result in increased 
bone formation and bone mass. Part of this direct anabolic effect 
of PTH has been ascribed to the ability of the hormone to pro-
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long osteoblast lifespan, resulting in accumulation of bone-form-
ing cells with consequent increase in bone mass and mechanical 
strength9-13. In addition, intermittent PTH has indirect actions 
in bone, by stimulating the production of IGF-1, which leads to 
pro-differentiation and pro-survival effects on osteoblasts14. Fur-
thermore, PTH also increases bone formation by reducing the 
expression of the antagonist of Wnt signaling Sost/sclerostin15. In 
addition to increasing bone mass, intermittent PTH affects the 
distribution of molecules in the organic bone matrix. For exam-
ple, the distribution of type I collagen in cortical bone is altered 
in menopausal women and in estrogen-deficient rats16,17. Moreo-
ver, PTH can also affect the expression of hyaluronan, as shown 
in cultured cells and in bones from mice treated with intermittent 
PTH18,19. Depending on its molecular weight, hyaluronan can in-
crease osteoclast recruitment and differentiation thereby increas-
ing bone resorption (low weight)20-23, or increase osteoblast dif-
ferentiation and mineralization (high weight)24. Furthermore, it 
has been shown that PTHrP, a molecule homolog to parathyroid 
hormone, regulates biosynthesis of proteoglycans in bone25, and 
that deletion of a proteoglycan impairs the skeletal formation and 
anabolic response to PTH26. This, together with reports that mice 
deficient in the proteoglycan perlecan have decreased anabolism 
in response to mechanical loading27, suggests that GAGs/proteo-
glycans and collagen are important in mediating bone response 
to hormonal and mechanical stimuli.
Gap junction proteins, molecules encoded by the GJ gene fam-
ily and known as connexins, mediate intercellular communica-
tions among bone cells. Six connexin molecules form a channel 
or connexon, which can align with a connexon on a neighboring 
cell to form a gap junction channel, allowing the communica-
tion between the two cells. Connexons are also present in the 
cell membrane to allow the communication of the cells with the 
extracellular environment. Connexin channels allow the pas-
sage of molecules <1.2 kDa 28,29. The potential requirement of 
one of the members of the connexin family of proteins, Cx43, 
for bone matrix homeostasis is evidenced by the expression of 
a dominant negative G60S mutant form for Cx43, which leads 
to altered synthesis of non-collagenous molecules and increased 
bone resorption30. Furthermore, collagen maturation is defective 
in mice lacking Cx43 in osteoblasts and osteocytes31. However, 
whether Cx43 expression in osteocytes is required to mediate the 
intermittent PTH effects in bone gain and whether its absence is 
associated with changes in the bone matrix is unknown31,32. 
Our previous studies show that Cx43 deletion results in altered 
bone material strength and decreased collagen cross-linking31, 
and that intermittent PTH administration affects the bone ma-
trix composition17. Moreover, mice lacking Cx43 in osteoblasts 
and osteocytes exhibit a reduced anabolic response to PTH32. 
We therefore aimed to determine whether osteocytic Cx43 is re-
quired to enable the effect of intermittent PTH administration on 
bone mass and matrix composition. 
The current study demonstrates that osteocytic Cx43 is not re-
quired for bone anabolism triggered by intermittent PTH admin-
istration in male mice. Moreover, PTH induced similar changes 
in the expression of non-collagenous components of the bone 
matrix in mice lacking Cx43 and littermate controls. However, 
the effects of the hormone on type I and type II collagen protein 
levels, and on collagen maturation are altered in the absence of 
osteocytic Cx43, suggesting that connexin is required for the ef-
fects of intermittent PTH on the bone matrix environment.
Materials and methods
Mice generation and PTH treatment
Mice harboring full length “floxed” Cx4333 (Cx43fl/fl) were 
mated with Cx43fl/fl mice expressing Cre recombinase under con-
trol of a DNA fragment containing 8kb of the murine dentin ma-
trix protein 1 promoter (DMP1) (Cx43fl/fl; DMP1-8kb-Cre)34. The 
same number of males and females from both genotypes were 
used as breeders. From this breeding, 2 genotypes were gener-
ated and used, as follows: Cx43fl/fl and Cx43fl/fl; DMP1-8kb-Cre. 
Male 4-month-old mice were subcutaneously injected once a day 
for 14 days with vehicle (0.9% saline, 10 μM β-mercaptoethanol 
and 0.01% acid acetic) (Cx43fl/fl, n=10 per group and Cx43fl/fl; 
DMP1-8kb-Cre mice, n=4 per group) or 100 μg/kg of human 
PTH(1-34) (Bachem California Inc., Torrance, CA ) dissolved 
in vehicle, as previously reported9 (Cx43fl/fl, n=8 per group and 
Cx43fl/fl; DMP1-8kb-Cre mice, n=8 per group). All mice used 
were of C57BL/6 background. Mice were fed a regular diet and 
water ad libitum, and maintained on a 12h light/dark cycle. Body 
weight was monitored once a month, from 1 to 4 months of age 
(before starting PTH administration). Mice were assigned to 
each experimental group based on spinal BMD. All protocols 
involving mice were approved by the Institutional Animal Care 
and Use Committee of Indiana University School of Medicine 
and from Federal University of São Paulo School of Medicine 
(UNIFESP, process #307/11). 
Bone mineral density (BMD) by dual energy x-ray  
absorptiometry (DXA)
Longitudinal BMD measurements were performed monthly 
from 1 to 4 months of age (before starting PTH injections) and 
after completion of 14-day PTH administration (4.5 months 
of age) by DXA using a PIXImus densitometer (G.E. Medical 
Systems, Lunar Division, Madison, WI). BMD measurements 
included whole body BMD (total BMD, excluding the head and 
tail), entire femur (femoral BMD) and L1-L6 vertebrae (spinal 
BMD)35. Calibration was performed before scanning with a 
standard phantom as recommended by the manufacturer. The 
percentage change BMD was calculated using the following for-
mula: [(final BMD - pre-treatment BMD) / pre-treatment BMD] 
x 100, in which pre-treatment BMD was measured at 4 months 
of age (before starting PTH administration) and final BMD was 
measured at 4.5 month of age (at the time of sacrifice).
Micro-computed tomography (μCT) analysis
L4 vertebrae and femora from mice at 4.5 months of age 
were dissected, cleaned of soft tissue and frozen at -20ºC until 
imaging. Bones were scanned wrapped in parafilm using 60kV 
source, 0.5 mm AI filter, 0.7 degree rotation and two-image av-
eraging at 6 μm pixel resolution on a Skyscan 1172 (SkyScan, 
Kontich, Belgium). Reconstruction and analysis were conducted 
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by Nrecon SkyScan software using a 2 smoothing, 5 ring artifact 
reduction, 20 beam-hardening correction and a similar threshold 
(0-0.10) for all animals. BV/TV was measured in the cancellous 
bone (1 mm of tissue) of the L4 vertebrae. Material density in 
distal femur and femoral mid-diaphysis was analyzed in 1 slice 
located 3 mm distant from cancellous region31,36,37. The termi-
nology and units used for μCT are those recommended by the 
Histomorphometry Nomenclature Committee of the American 
Society for Bone and Mineral Research (ASBMR)38.
RNA extraction and quantitative RT-PCR (qPCR)
Lumbar vertebrae (L6) were thawed and total RNA was 
extracted using Trizol reagent (Invitrogen), as previously re-
ported39. mRNA was converted to cDNA using a high capac-
ity cDNA reverse transcription kit (Applied Biosystems, Fos-
ter City, CA). qPCR was performed using the ∆Ct method40, 
with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as the housekeeping gene. Primers and probes were designed 
using the Assay Design Center (Roche Applied Science, In-
dianapolis, IN) or were commercially available (Applied Bio-
systems, Foster City, CA). 
Immunohistochemistry
Whole femora were dissected and fixed in 10% neutral-buff-
ered formalin for 48h, followed by demineralization in 10% eth-
ylenediaminetetraacetic acid (EDTA), pH 7.0 for 10 days, with 
changes of the EDTA solution every 3 days. Next, distal femora 
were embedded in paraffin and sectioned through the frontal 
plane at 5 μm thickness. Sections were then deparaffinized, re-
hydrated and incubated with 3% H2O2 in methanol for 5 min to 
inhibit endogenous peroxidase and with 1% BSA for 30 min to 
block nonspecific binding sites. For proteins identification and 
quantification, sections were incubated with primary antibody 
against collagen 1a1 (1:2000), collagen 2a1 (1:150) and decorin 
(1:300) (Santa Cruz Biotechnology, Santa Cruz, CA) in PBS+1% 
BSA overnight. Negative controls were obtained by replacing 
the primary antibody by PBS+1% BSA. After rinsing with PBS, 
sections were incubated by corresponding secondary antibod-
ies conjugated with horseradish peroxidase (HRP) (Santa Cruz 
Biotechnology, Santa Cruz, CA) for 30 min. Samples were de-
veloped with DAB substrate-chromogen system (Dako North 
America Inc., Carpinteria, CA) and mounted with entellan®. 
All sections were evaluated by two blinded investigators. For 
quantitative assessment, all slides were stained in one batch. Two 
different sections from 4-8 animals/group (400x magnification) 
were used, and 40 different points were analyzed within distal 
cortical compartment in order to calculate the average of the den-
sitometric grey levels using an image analysis system (AxioVi-
sion Rel. 4.6., Carl Zeiss, Germany). All cortices were evaluated 
at 390 μm below the lowest point of the growth plate17 in an area 
of 1.5 mm2. The values are expressed as arbitrary units (a.u.)41,42.
Picrosirius red staining
Bone embedded in paraffin and sectioned through the fron-
tal plane at 5 μm thickness were deparaffinized, rehydrated, and 
stained using the modified picrosirius red technique43-45. Histo-
chemistry for picrosirius red was used to reveal the collagen fib-
ers. Briefly, bone sections were incubated for 10 minutes in 0.2% 
aqueous phosphomolybdic acid to render the cytoplasm and elas-
tin colorless and then stained in a 0.1% solution of Sirius red in 
saturated aqueous picric acid for 90 minutes, washed in 0.01N 
HCl for 2 minutes, dehydrated, cleaned, and mounted with entel-
lan®. Two sections from each mouse were imaged (200x mag-
nification) in distal femur area under a microscope Axioskop 
40 microscope (Carl Zeiss, Germany) equipped with polarizing 
filters using an AxioCamMRc 5 digital camera (Carl Zeiss, Ger-
many) by two blinded-investigators at 390μm below the lowest 
point of the growth plate (to exclude the primary spongiosa)17. 
Approximately 1.5 mm2 of cancellous and 1.2 mm of cortical 
area were examined. The average from two sections of 4-6 ani-
mals/group was scored from 1 to 5, with 1 indicating 100% of 
reddish birefringence; 2, 75% of reddish and 25% of greenish 
birefringence; 3, 50% of reddish and 50% of greenish birefrin-
gence; 4, 25% of reddish and 75% of greenish birefringence; and 
5, 100% of greenish birefringence. 
Statistical analysis
Data were analyzed by using SigmaPlot (Systat Software 
Inc., San Jose, CA). Multiple comparisons for the 4 groups were 
performed using two-way ANOVA test followed by Student-
Newman-Keuls post-hoc analysis to determine the significance 
of the difference among treatments, and considered significant 
when p<0.05. All values are reported as the mean ± standard 
deviation (SD).
Results
Expression of Cx43 in osteocytes is not required for bone anabo-
lism induced with intermittent PTH administration
The absence of Cx43 specifically in osteocytes of male mice 
did not alter body weight or total body, femoral, or spinal BMD 
assessed longitudinally from 1 to 4 months of age (Figure 1a). 
Intermittent PTH administration for 14 days increased BMD in 
both control Cx43fl/fl and Cx43fl/fl; DMP1-8kb-Cre mice (Figure 
1b). Thus, PTH administration induced a significant increase 
in BMD in all sites, without genotype x treatment interaction, 
indicating that PTH has similar effects in mice expressing or 
lacking osteocytic Cx43 (Table 1). This analysis also showed that 
mice lacking Cx43 in osteocytes and treated with vehicle lose 
more spinal BMD than control littermates during the 14 days of 
the experiment, suggesting that osteocytic Cx43 is required for 
maintaining spinal bone mass in adult male mice. Cancellous 
bone volume (BV/TV) was increased in the lumbar vertebrae in 
mice from both genotypes treated with intermittent PTH (Figure 
1c and Table 1). 
Intermittent PTH administration increases mRNA levels of 
genes associated with osteoblast differentiation in vertebral 
bone, independently of osteocytic Cx43 expression
Targeted-deletion of Cx43 from osteocytes or intermittent 
PTH administration did not alter the expression of GAGs (has1, 
48
R. Pacheco-Costa et al.: Osteocytic Cx43 is dispensable for PTH effect
Figure 1. Deletion of Cx43 in osteocytes does not change bone mass and is not required for intermittent PTH-mediated anabolism. (a) Body weight 
and total, femoral and spinal BMD was assessed monthly from 1 to 4 months by DXA in Cx43fl/fl and Cx43fl/fl; DMP1-8kb-Cre male mice. The sym-
bols correspond to mean ± SD, n=18-23. (b) BMD percentage change was calculated using the BMD values at the end of treatment (4.5 months of 
age) and at the beginning of PTH treatment (4 months of age) for each animal. Bars represent mean ± SD, n=4-10. (c) Cancellous bone volume (BV/
TV) was assessed by μCT in L4 vertebrae at 4.5 months of age. Bars represent mean ± SD, n=4-10. * p<0.05 versus vehicle by two-way ANOVA.
Table 1. Statistical analysis of the effect of intermittent PTH administration on BMD in mice expressing or lacking Cx43 in osteocytes. Two-way 
ANOVA, followed by Student-Newman-Keuls post-hoc test. 
BMD BV/TV
Source of variation total body femur spine vertebrap value p value p value p value
Genotype 0.471 0.162 0.019 0.767
Treatment 0.028 <0.001 0.002 <0.001
Genotype x treatment 0.654 0.599 0.088 0.086
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Figure 2. Intermittent PTH administration increases the expression of osteoblast markers, independently of osteocytic Cx43 expression. Gene 
expression in L6 vertebrae from Cx43fl/fl and Cx43fl/fl; DMP1-8kb-Cre male mice and after treatment for 14 days with injections of PTH or vehicle 
control. (a) GAGs-, (b) proteoglycans-, (c) collagen-, and (d) osteoblast-related genes were measured at 4.5 months of age by qPCR and corrected by 
GAPDH. Bars represent mean ± SD, n=4-10. * p<0.05 versus vehicle by two-way ANOVA.
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has2, chpf and chsy3) or proteoglycans (fibronectin, biglycan, 
decorin and fibromodulin), when compared to littermate controls 
(Figure 2a and b). On the other hand, mRNA expression for type I 
collagen (col1a1) was increased in vertebrae from both genotypes 
after PTH injections, but it was not altered by Cx43 deletion (Fig-
ure 2c and Table 2). We next investigated whether increased col-
lagen synthesis was followed by collagen maturation; in a process 
conducted in part by lysyl oxidase (lox) family genes. The expres-
sion of lox was significantly affected by both the genotype and 
the treatment, with higher expression in Cx43fl/fl; DMP1-8kb-Cre 
mice treated with PTH. However, we did not find a significant 
interaction between genotype and treatment for this gene. On the 
other hand, the levels of loxl1 were affected by the genotype, with 
Cx43fl/fl; DMP1-8kb-Cre mice expressing higher levels; but not 
by PTH administration. In addition, mRNA levels of alkaline 
phosphatase (alp), runx2, osteocalcin, and bone sialoprotein were 
increased by intermittent PTH administration in both Cx43fl/fl and 
Cx43fl/fl; DMP1-8kb-Cre mice (Figure 2d and Table 2). 
Intermittent PTH administration increases the levels of type I 
collagen protein in the absence and type II collagen in the pres-
ence of osteocytic Cx43
Visual inspection of bone sections stained for type I and type 
II collagen and decorin suggested similar protein expression in 
bone sections from vehicle-treated Cx43fl/fl or Cx43fl/fl; DMP1-
8kb-Cre mice (Figure 3a, c, f, h, k and m). Densitometric analy-
sis confirmed that deletion of osteocytic Cx43 did not affect the 
expression of type I collagen, type II collagen or decorin, with 
similar levels in vehicle-treated Cx43fl/fl and Cx43fl/fl; DMP1-8kb-
Cre mice (Figure 3e, j and o). We also found that vehicle-treated 
Cx43fl/fl exhibited similar type I collagen levels when compared 
to the corresponding intermittent PTH-treated mice (Figure 3a 
and b). On the other hand, PTH-treated Cx43fl/fl; DMP1-8kb-Cre 
mice showed a more intense type I staining, compared to vehicle-
treated mice of the same genotype (Figure 3c and d). The visual 
examination was confirmed by densitometric quantification of 
the sections, with a significant increase in type I collagen protein 
level by 29% only in Cx43fl/fl; DMP1-8kb-Cre mice treated with 
intermittent PTH, compared to vehicle-treated mice (Figure 3e), 
consistent with the increase in lox levels only in mice lacking 
Cx43 in osteocytes treated with the hormone. As for type I colla-
gen, the expression of type II collagen was not affected by Cx43 
deletion (Figure 3f and h). However, the intensity of staining for 
this collagen is higher in bone sections from Cx43fl/fl mice treated 
with intermittent PTH (Figure 3g) compared to the same mice 
treated with vehicle (Figure 3f). On the other hand, the expres-
sion of type II collagen in Cx43fl/fl; DMP1-8kb-Cre mice was not 
affected by PTH administration (Figure 3h and i). Densitometric 
quantification of the sections confirmed the increase in type II 
collagen expression induced by PTH only in Cx43fl/fl (Figure 3j). 
The expression of decorin, a proteoglycan associated with col-
lagen fibrillogenesis, was not altered in bone sections from in-
termittent PTH-treated Cx43fl/fl or Cx43fl/fl; DMP1-8kb-Cre mice 
when compared to their littermates receiving vehicle injections 
(Figure 3k-o). 
Deletion of osteocytic Cx43 impairs collagen maturation in-
duced by intermittent PTH administration
Cx43fl/fl mice treated with vehicle exhibited a slight predomi-
nance of reddish in relation to greenish birefringence in cortical 
(Figure 4a) and cancellous (Figure 4b) bone sections, with a rela-
tive score of approximately 2. Statistical analysis did not reveal 
difference in birefringence between Cx43fl/fl and Cx43fl/fl; DMP1-
8kb-Cre mice, indicating that collagen maturation is independent 
on the expression of Cx43 in osteocytes (Table 3). Intermittent 
PTH administration decreased greenish birefringence in the cor-
tical bone to a score of approximately 1 in Cx43fl/fl mice (Figure 
4c and Table 3), indicating the presence of more mature colla-
gen fibers. On the other hand, the hormone did not modify the 
score in cancellous bone of Cx43fl/fl mice (Figure 4d), indicating 
changes in collagen maturation only in the cortical bone com-
partment. Deletion of Cx43 from osteocytes did not modify the 
collagen birefringence pattern in cortical (Figure 4e) or in can-
cellous bone (Figure 4f), when compared to control littermates 
(Figure 4a-b and Table 3). Furthermore, similar to Cx43fl/fl mice 
(Figure 4d), intermittent PTH did not alter the pattern of col-
lagen maturation in cancellous bone in Cx43fl/fl; DMP1-8kb-Cre 
mice (Figure 4h). However, unlike controls expressing osteocytic 
Cx43 (Figure 4c), intermittent PTH administration did not alter 
the reddish/greenish pattern in cortical bone, with a relative score 
of approximately 2 in mice lacking Cx43 in osteocytes (Figure 
4g and Table 3). This suggests that Cx43 expression in osteocytes 
is required for the effect of intermittent PTH on collagen matura-
tion only in cortical bone.
collagen-related genes osteoblast-related genes
Source of variation col1a1 lox loxl1 alp runx2 osteocalcin bspp value p value p value p value p value p value p value
Genotype 0.176 0.042 0.028 0.228 0.260 0.907 0.520
Treatment <0.001 0.048 0.220 <0.001 <0.001 <0.001 <0.001
Genotype x treatment 0.586 0.138 0.431 0.462 0.709 0.084 0.980
Table 2. Statistical analysis of the effect of intermittent PTH administration on gene expression in mice expressing or lacking Cx43 in osteocytes. 
Two-way ANOVA, followed by Student-Newman-Keuls post-hoc test. 
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Figure 3. Intermittent PTH increases 
type I or type II collagens, depend-
ing on the absence or presence of 
osteocytic Cx43. Bone sections from 
male mice at 4.5 months of age were 
subjected to type I collagen immu-
nohistochemistry (diffuse brown 
color). Photomicrographs show cor-
tical region of Cx43fl/fl mice treated 
with vehicle (a) or with intermittent 
PTH (b). Inset shows a representa-
tive image from negative control for 
the reactions. Outlined in red shows 
the regions where measurements were 
performed. Photomicrographs from 
cortical region of Cx43fl/fl; DMP1-8kb-
Cre mice treated with vehicle (c) or 
with the intermittent PTH (d) treat-
ed. Scale bars represent 100 μm. (e) 
Quantification of type I collagen. Bars 
represent mean ± SD, n= 4-8 mice per 
group. *p<0.05 versus corresponding 
vehicle by two-way ANOVA. Bone 
sections from male mice at 4.5 months 
of age stained for type II collagen (dif-
fuse brown color). Photomicrographs 
from cortical and cancellous region 
of Cx43fl/fl mice treated with vehicle 
(f) or with intermittent PTH (g) are 
shown. Inset shows a representative 
image from negative control for the re-
actions. Photomicrographs from cor-
tical and cancellous region of Cx43fl/
fl; DMP1-8kb-Cre mice treated with 
vehicle (h) or with intermittent PTH 
(i) are shown. Scale bars represent 
200 μm. (j) Quantification of type II 
collagen. Bars represent mean ± SD, 
n=4-8 mice per group. *p<0.05 ver-
sus corresponding vehicle by two-way 
ANOVA. Bone sections from femora 
from male mice at 4.5 months of age 
stained for decorin (diffuse brown 
color) are shown. Photomicrographs 
showing cortical region of distal fe-
mur of Cx43fl/fl mice treated with vehi-
cle (k) or with intermittent PTH (l) are 
included. Inset shows a representative 
image from negative control for the re-
actions. Photomicrographs from corti-
cal region of Cx43fl/fl; DMP1-8kb-Cre 
mice treated with vehicle (m) or with 
intermittent PTH (n) are shown. Scale 
bars represent 100 μm. (o) Quantifica-
tion of decorin. Bars represent mean 
± SD, n=4-8 mice per group. *p<0.05 
versus corresponding vehicle by two-
way ANOVA. Ct= cortical, Tb= tra-
becula, Ma= bone marrow.
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Figure 4. The effect of intermittent PTH on collagen birefringence in cortical bone is impaired in mice lacking osteocytic Cx43. Bone sections 
from femora from male mice at 4.5 months of age were stained by picrosirius red and visualized under polarized light microscopy. Photomicro-
graphs from cortical (a) and cancellous bone (b) of Cx43fl/fl vehicle-treated mice and cortical (c) and cancellous bone (d) of intermittent PTH-treated 
mice. Photomicrographs from cortical (e) and cancellous bone (f) of Cx43fl/fl; DMP1-8kb-Cre vehicle-treated mice and cortical (g) and cancellous 
bone (h) of intermittent PTH-treated mice. The scale bar represents 100 μm. Images are representative of 4-6 mice per group.
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Deletion of Cx43 or treatment with PTH does not change  
material density
We also examined the effects of genetic deletion of osteo-
cytic Cx43 or pharmacologic administration of PTH on bone 
material density, an index of mineralization level of the tissue 
independent of bone volume, assessed by μCT37. Neither dele-
tion of Cx43 from osteocytes nor intermittent PTH administra-
tion alter the material density in the distal femur and femoral 
mid-diaphysis from Cx43fl/fl or Cx43fl/fl; DMP1-8kb-Cre mice 
(Figure 5), indicating that 14-day treatment with PTH does not 
affect bone mineralization. 
Discussion
We show in the current study that expression of Cx43 in os-
teocytes is not required for the anabolic effect induced by inter-
mittent PTH administration in male mice. Similarly, deletion of 
osteocytic Cx43 does not affect the mRNA levels of collagen 
and non-collagenous proteins in vertebral bone. However, it al-
ters the effect of PTH on type I and type II collagen protein 
levels and blunts the effect of the hormone on collagen matura-
tion in cortical bone. 
Previous findings showed that Cx43 expression in cultured 
osteoblastic cells is necessary for cAMP accumulation46,47 and 
for the expression of cAMP-dependent genes47 induced by PTH 
treatment, thus indicating the importance of Cx43 molecule for 
intracellular signaling induced by the hormone. Moreover, re-
duced bone formation, defective osteoblast function, and, overall, 
decreased anabolic response to intermittent PTH administration 
were reported in mice lacking Cx43 in osteoblasts32. On the con-
trary, our findings show a full anabolic response of intermittent 
PTH administration independently of the presence (Cx43f/f mice) 
or the absence (Cx43fl/fl; DMP1-8kb-Cre mice) of osteocytic 
Cx43 in male mice, with increased total body, femoral and spinal 
BMD. Furthermore, cancellous bone volume in the lumbar ver-
tebrae is also increased in mice treated with intermittent PTH, 
independently of osteocytic Cx43 expression. Recently, we re-
ported that females lacking osteocytic Cx43 also respond to in-
termittent PTH administration48. Taken together with published 
evidence, the results reported in this manuscript indicate that 
Cx43 expression in osteoblasts, but not in osteocytes is required 
for bone formation induced by intermittent PTH administration.
The characterization of molecules in bone matrix is crucial 
for understanding how the matrix behaves in the absence of os-
teocytic Cx43, and also in the face of intermittent PTH admin-
istration, since modifications in the distribution and synthesis of 
collagen and other organic molecules are reflected on cell fate 
and fracture risk16,49. We dedicated part of the current study to 
investigate collagens and GAGs/proteoglycans, molecules abun-
dantly expressed in the bone tissue. However, we were not able to 
detect pronounced changes in bone matrix components or in the 
Cx43fl/fl Cx43fl/fl + PTH Cx43fl/fl;Cre Cx43fl/fl;Cre + PTH
Cortical bone 2.0 ± 0.0 1.1 ± 0.3a 1.7 ± 0.5 1.9 ± 0.2
Cancellous bone 1.6 ± 0.5 1.8 ± 0.3 1.8 ± 0.5 1.8 ± 0.4
Values are mean ± SD. n=4-6. p<0.05 by two-way ANOVA.
a Indicates significant difference versus vehicle-treated Cx43fl/fl mice.
Table 3. Quantification of collagen birefringence in cortical and cancellous bone of mice lacking Cx43 and the corresponding littermate controls, 
treated with vehicle or intermittent PTH.
Figure 5. Material density is not change by either genotype or treatment. Material density was assessed by μCT in cancellous bone at the distal 
femora and in cortical bone at the femoral mid-diaphysis from Cx43fl/fl and Cx43fl/fl; DMP1-8kb-Cre mice at 4.5 months of age. Bars represent mean 
± SD, n=4-10.
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level of mineralization in mice in which Cx43 was deleted from 
osteocytes, indicating that osteocytic Cx43 is not require for the 
formation of either organic or inorganic components of the bone 
matrix under basal (untreated) conditions.
Type I collagen fibers are the most abundant component of 
organic bone matrix. Studies have shown increased type I col-
lagen expression after intermittent PTH administration in human 
bone tissue and type II collagen in mesenchymal stem cells16,50. 
Therefore, we used both types of collagen to verify whether PTH 
increases the expression of these collagens and whether they 
would be affected by deletion of osteocytic Cx43. Our evidence 
suggests a divergent role of Cx43 on the expression of collagen 
induced by intermittent PTH administration: while the effect of 
intermittent PTH on type I collagen is only present in mice lack-
ing osteocytic Cx43, the effect of the hormone on type II colla-
gen is only observed when osteocytic Cx43 is expressed. Further 
studies are required to determine the molecular basis of this dis-
parate effect of Cx43 in osteocytes. 
Altered collagen is associated with bone fragility in animals 
and humans16,51-54 and the degree of collagen fibers maturation is 
revealed through their thickness and consequently can be assess 
by determining their birefringence55. Moreover, a relationship 
between collagen cross-linking and mineralization of bone ma-
trix was reported in monkeys and humans treated with low doses 
of intermittent PTH for long term, indicating that PTH decreased 
the maturity of collagen fibers56,57. In the present study, we evalu-
ated collagen birefringence behavior by picrosirius red/polariza-
tion, a well-known method to assess collagen maturation17,43-45,58. 
Immature fibers are thinner, and under light polarized show a 
greenish birefringence, whereas mature fibers are thicker and 
show a pattern of yellow to reddish birefringence59,60. We did 
not observe a difference in pattern of collagen birefringence in 
Cx43f/f and Cx43fl/fl; DMP1-8kb-Cre mice. This evidence con-
trasts with findings in mice lacking Cx43 from osteoblasts, in 
which disorganization of collagen was found using the same 
picrosirius/polarization method61, suggesting that osteocytic 
Cx43 does not modulate the behavior of collagen fibers. On the 
other hand, the results of the current study indicate that while 
intermittent PTH administration induced a response in collagen 
maturation in cortical bone of Cx43fl/fl mice, it failed to do so in 
Cx43fl/fl; DMP1-8kb-Cre mice. We cannot rule out the possibil-
ity that the change of collagen birefringence is associated with 
changes in type II collagen, since the expression of this protein 
was increased in bone section of distal femora. It is also possible 
that Cx43fl/fl; DMP1-8kb-Cre mice exhibit a delayed response to 
intermittent PTH and that the hormone would induce collagen 
maturity in the cortical compartment given enough time. 
As discussed above, we have previously reported that absence 
of osteocytic Cx43 is associated with impaired collagen cross-
linking, and with changes in the expression of enzymes associ-
ated with collagen cross-linking31. Thus, we investigated whether 
genes related to collagen cross-linking (lox, loxl-1/4) were al-
tered, in order to provide a potential explanation for why the ef-
fect of the hormone in the bone matrix is impaired when Cx43 
is absent in osteocytes. We found that overall mRNA levels were 
not altered by either the genotype or the treatment in vertebral 
lysates. Even though the statistical analysis showed a genotype 
effect on the levels of lox and loxl1, the difference in vehicle-
treated mice is not clear and the overall significance seems to be 
driven by the PTH treatment. 
We also investigate the effect of the genetic (deletion of osteo-
cytic Cx43) and pharmacologic manipulations (intermittent PTH 
administration) on GAGs and proteoglycans. GAGs presence is 
related to the development and structural consolidation of the 
collagen fibers in the bone matrix62. In addition, mice deficient 
of biglycan or decorin, both chondroitin-rich proteoglycans, ex-
hibit disorganization in the shape and size of the collagen fib-
ers63, and removal of decorin is a potential cause for fusion of 
the collagen fibers64. Indeed, changes in GAGs/proteoglycans 
reflect in the collagen fibers since these elements are intrinsi-
cally associated, as reported elegantly in a morphological study 
showing that decorin and biglycan inhibits totally or partly the 
collagen fusion65. We therefore focused our study on decorin 
and biglycan expression because of their intrinsic association 
with collagen fibers66-70. Our study did not show differences in 
the mRNA expression of these genes or in decorin levels by im-
munohistochemistry, suggesting that these proteoglycans are not 
changed in Cx43-deficient or in intermittent PTH-treated mice. 
Supporting these findings, expression of biglycan is not affected 
in a model of PTH-related protein-deficient mice25. Thus, it is 
possible to conclude that biglycan and decorin proteoglycans are 
not responsible for collagen modifications when osteocytic Cx43 
was deleted. Our data suggests that osteoblastic cells that still ex-
press Cx43 are able to respond to intermittent PTH administra-
tion, consequently producing proteoglycans, collagens and other 
molecules associated with bone formation16,25,71,72. In support of 
this notion, we detected in bone preparations increased expres-
sion of runx2, alkaline phosphatase, osteocalcin, bone sialopro-
tein and type I collagen, genes associated with differentiation, 
formation and activity of osteoblasts and known to respond to 
daily PTH injections9,16,32,73-75. 
In summary, the current study shows that osteocytic Cx43 
expression is not required for the full anabolic response to the 
intermittent PTH administration in male mice; and that this con-
nexin is involved partially in the effect of PTH on the bone ma-
trix environment.
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